Skip to content

Michael Banov

2 papers in the library · 2 citations · publishing 2025-2026

Papers

Interdisciplinary, Delphi-driven consensus guidelines on the use of intravenous ketamine infusions for depressive disorders from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners (ASKP3).

J Affect Disord May 16, 2026 David S. Mathai, Madeleine Cluck, Amna M. Aslam et al. 1 citation

A panel of experts from the American Society of Ketamine Physicians, Psychotherapists, and Practitioners used a Delphi process to develop consensus guidelines for administering intravenous ketamine infusions to treat depressive disorders. The guidelines provide recommendations on patient selection, dosing, safety monitoring, and treatment protocols, aiming to standardize clinical practice and improve patient outcomes. The consensus reflects agreement among specialists on best practices for this off-label use of ketamine.

Efficacy of Intravenous Racemic Ketamine on Global Severity and Individual Symptoms of Depression

Journal of Clinical Psychopharmacology September 25, 2025 Rachel Landrum, Amanda M. Raines, Philip D. Harvey et al. 1 citation

Maintenance intravenous racemic ketamine therapy produced significant, persistent, and broad symptom relief for treatment-resistant depression. Reductions occurred in both clinician-rated (Montgomery-Åsberg Depression Rating Scale) and patient-reported (Patient-Health Questionnaire-9) depression scores. Changes in individual symptoms were similar to prior trials: suicidal ideation and depressed mood improved most, while appetite disturbance improved least.